SUPN Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 8.8% compared to Supernus Pharmaceuticals's net margin of 16.9%. Supernus Pharmaceuticals's return on equity of 7.61% beat Corcept Therapeutics's return on equity of 23.78%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 18.47%. On the other hand Corcept Therapeutics has an analysts' consensus of $139.50 which suggests that it could grow by 22.13%. Given that Corcept Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.901, which suggesting that the stock is 9.882% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.145, suggesting its less volatile than the S&P 500 by 85.456%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $174.2M, which are smaller than Corcept Therapeutics quarterly revenues of $181.9M. Supernus Pharmaceuticals's net income of $15.3M is lower than Corcept Therapeutics's net income of $30.7M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 24.77x while Corcept Therapeutics's PE ratio is 92.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.77x versus 19.21x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 8.8% compared to Supernus Pharmaceuticals's net margin of 32.59%. Supernus Pharmaceuticals's return on equity of 7.61% beat Eli Lilly and's return on equity of 80.24%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 18.47%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.35%. Given that Eli Lilly and has higher upside potential than Supernus Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.901, which suggesting that the stock is 9.882% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Supernus Pharmaceuticals quarterly revenues are $174.2M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Supernus Pharmaceuticals's net income of $15.3M is lower than Eli Lilly and's net income of $4.4B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 24.77x while Eli Lilly and's PE ratio is 70.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.77x versus 16.58x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 8.8% compared to Supernus Pharmaceuticals's net margin of 2.31%. Supernus Pharmaceuticals's return on equity of 7.61% beat Pfizer's return on equity of 8.91%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 18.47%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 23.36%. Given that Pfizer has higher upside potential than Supernus Pharmaceuticals, analysts believe Pfizer is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.901, which suggesting that the stock is 9.882% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.67% to investors and pays a quarterly dividend of $0.43 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $174.2M, which are smaller than Pfizer quarterly revenues of $17.8B. Supernus Pharmaceuticals's net income of $15.3M is lower than Pfizer's net income of $410M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 24.77x while Pfizer's PE ratio is 17.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.77x versus 2.27x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 8.8% compared to Supernus Pharmaceuticals's net margin of 25.08%. Supernus Pharmaceuticals's return on equity of 7.61% beat Zoetis's return on equity of 49.71%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 18.47%. On the other hand Zoetis has an analysts' consensus of $199.99 which suggests that it could grow by 21.46%. Given that Zoetis has higher upside potential than Supernus Pharmaceuticals, analysts believe Zoetis is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.901, which suggesting that the stock is 9.882% less volatile than S&P 500. In comparison Zoetis has a beta of 0.925, suggesting its less volatile than the S&P 500 by 7.51%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.09% to investors and pays a quarterly dividend of $0.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Supernus Pharmaceuticals quarterly revenues are $174.2M, which are smaller than Zoetis quarterly revenues of $2.3B. Supernus Pharmaceuticals's net income of $15.3M is lower than Zoetis's net income of $581M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 24.77x while Zoetis's PE ratio is 30.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.77x versus 8.09x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.